{"name":"German Low Grade Lymphoma Study Group","slug":"german-low-grade-lymphoma-study-group","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPQXJCOV8ybXhCQm1ORmw4X3h2ZDg5d3lua2FJVjlCZExDenNzZVJTU04wd2xkU2Rac3IxMWEyaHNYTmpqX2NQREd1VURIdVF6LUhzOEYwWloxV1VwOGxOQUxadF90VlNPVFA2Q2pPM3FBWF9ETUM4aDF6SEYzR2t4djVjZHY3OXdtQ05z?oc=5","date":"2024-07-03","type":"regulatory","source":"The Lancet","summary":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial - The","headline":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymph","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxORFhIbEhoMVh1YkpYakZfZW4wT0s4a2prdGJGMEZYaDVzdnM2Y1h0QkRDWFdhVG1VdWhZY2JGcnlxNGVGbGZ1SjlyNnoxTE5SOGJwUDhBOXRqR0Z0UFhrU2psU3hQSFhXN2xHZWpOYTBLSnZfT01aUnV1UG5sQkJOWmtueUNvM1RBTVJJYVZLUjBXeWM?oc=5","date":"2024-02-08","type":"pipeline","source":"Frontiers","summary":"Rituximab Concentration Varies in Patients With Different Lymphoma Subtypes and Correlates With Clinical Outcome - Frontiers","headline":"Rituximab Concentration Varies in Patients With Different Lymphoma Subtypes and Correlates With Clinical Outcome","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTE5HOFBCRmdxMFlqWHB5eDNZNngzNUtQRnV1RW93WlJvcXNoaWw2Qm5EczBJb0k5bDNtbWI2a1k2Y1B2UWpMYzNJNTM0TTFDMTZjd1dCRV9GUQ?oc=5","date":"2024-02-01","type":"pipeline","source":"jnm.snmjournals.org","summary":"Reply: [18F]FDG and Lymphomas: Still a Winning Golden Couple in the Era of FAPI-Based Radiotracers - jnm.snmjournals.org","headline":"Reply: [18F]FDG and Lymphomas: Still a Winning Golden Couple in the Era of FAPI-Based Radiotracers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE15ck9FZnhPU1BOazV6eWlpX1gyZXgybHBWQm5TdTlJbklWNGpMQWkxREM4cURFU0VvaFZYTFZ1Q2tCMnc5bXBoNENaSWNKRDRXMmNlRkthZXd2RjIyUEVn?oc=5","date":"2022-08-16","type":"trial","source":"Nature","summary":"Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT","headline":"Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-trans","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1WSjAzWkpEM2puQkdrc0VNbzRpSXR5WDIyeVpmS3Z6WmdnRzljQ3pHQ05BMkdYdEwtNnZyTVRrbnl3elpqTXo3dWpLUnhkR21BSHNSSzByb2JlSkZWU0FN?oc=5","date":"2022-06-22","type":"regulatory","source":"Nature","summary":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms - Nature","headline":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxOcWxGbUJEczEwZ1loUm1WX3R3WF9PaXZvZVpJTmRBS2t6OWw2d1NqOGdDaUE1N0FmZndGYXlMYmlkSnJEbWh2ZktHZ0w2TzNhWEotR3FLTTl0WjJNNzNBX2RSOUpvMkFiVUd2SmpiakxhODZlZk9HRl9hQmRfUVhTRUlNbw?oc=5","date":"2020-06-14","type":"pipeline","source":"CancerNetwork","summary":"The Place of Transplantation in Mantle Cell Lymphoma - CancerNetwork","headline":"The Place of Transplantation in Mantle Cell Lymphoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxOdTVhRzFQZXQyWTNKLUwySS1jckFqVEdWeU9yRzdWNkxrcFQtNTgxMVluR2JKZUctZ01yMWFqT1UtZVQ2RVdobHk0ZC05MWNseWtiYWFGSGUwZmhrb1NWWm95cHd2NFF0T3FGVWg4ZEsxRFBCRDIyeHctb2tKZjgwenhKTQ?oc=5","date":"2020-06-11","type":"pipeline","source":"CancerNetwork","summary":"Lymphoma 2006: Classification and Treatment - CancerNetwork","headline":"Lymphoma 2006: Classification and Treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQbWFvZXY4V3NGQ1Z4UDVoQ1lRaGQ3OWp0czU3a1dmNk53ald5amNRNFM3a0YzWndxZzhtNWxNZlhOWDdUcDdMRzZ5Y3hhWjRMZG9PZ1RFelNkTmxEZGcyeWVFRngtdUlJYlltQUgtaHA1RVpIckM0NFNyX0YtcXBINHVsazR5cV8wTXVFOE9Lb3pqVWRsTXZMTGh1UFZHQkdrTUo3djFqM3BBdTJDUW1GV3VZb19TQndFRDZ1YnNYbmpLNW8?oc=5","date":"2020-04-28","type":"pipeline","source":"European Medical Journal","summary":"Practical Insights into Managing Follicular Lymphoma: What’s Best for Patients? - European Medical Journal","headline":"Practical Insights into Managing Follicular Lymphoma: What’s Best for Patients?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTFAzVDQ4cWF0OFQ4TUMyRko4MUdwald5MS15Nzg4al8yZXNXenl3MXByay1Ea083RGk4TWR3M2Ytb0t3RGt5cVVpWk83NmV6ZzhnZVFzYmRhNUgwZlZpUDJteg?oc=5","date":"2018-09-05","type":"pipeline","source":"NEJM","summary":"Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma - NEJM","headline":"Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPN3dSNmNLOWFuX182TW5kNVB5cWdzYy1QQkQtZ3VwaFVmNDQxZ3VlWi1xYXlNVm9GYkwtcU51cnNwNlRJemg2ekU4RTFLdUIxejdubWU0SUJ3YWRndGJHbUFkNGJYRkttaEJfR2NfX01UNUE4TmZHMnZuMWpTazV4RU85ZU1WdkZ6eURUWU5sZWE?oc=5","date":"2018-05-31","type":"regulatory","source":"The Lancet","summary":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority tri","headline":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cel","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTFB3Q3YzQ21fM2ptZER5UVBQUEZwN2tmTERwekYwY2RCNXJQSEsxTkZpVXoxd203akg3cHR2SlJjbGZoWUh0RnpBa0pHaXN2U3oxR2wwWTZya2hpZ1JpWGE4VA?oc=5","date":"2017-10-05","type":"pipeline","source":"NEJM","summary":"Obinutuzumab for the First-Line Treatment of Follicular Lymphoma - NEJM","headline":"Obinutuzumab for the First-Line Treatment of Follicular Lymphoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxOZ1hwSVkyZS0tNHJiZU51a3RUT1dwZk9oMDJUWVpZMFlNNFBSZ3pCdFJzNGRqWG9LdE9vTTFGMWxyLXhnZEF6bGVQX1JXTl9Selktakp5WGMwejV6a2JWc2hKTU1Wc2hZYzMxR0puMVVvTlNvQ0hVZEM1OGhCd3l3b3cxMEhiUE9Xam1uR200ZGxtSF8tSlczd0YyT295OThyM3Ixd0RrdnB5M1lLcjBrOWJIV2k0aTlpTmhnMG9KNFRMZkxKTDlGRHpOQVFweXNGRC1FaDlTUDZCSGUtdWNtTmlqaHQtMTE5aVlyZXdpZVA?oc=5","date":"2017-06-02","type":"regulatory","source":"Hematology Advisor","summary":"Rituximab in the Treatment of Follicular Lymphoma: the Future of Biosimilars in the Evolving Therapeutic Landscape - Hematology Advisor","headline":"Rituximab in the Treatment of Follicular Lymphoma: the Future of Biosimilars in the Evolving Therapeutic Landscape","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}